fluorobenzenes has been researched along with Neointima in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, SW; Fang, SY; Hsu, CH; Huang, CC; Lam, CF; Lin, Y; Roan, JN; Tsai, YC | 1 |
| Chang, SH; Chen, WJ; Hsieh, IC; Hsu, MY; Hung, KC; Lee, CH; Lin, YH; Liu, SJ; Wang, CJ; Wen, MS; Yeh, YH | 1 |
| Ikeda, T; Ikuta, S; Iwanaga, Y; Kobuke, K; Miyazaki, S; Ueno, M; Yamaji, K; Yamamoto, H; Yasuda, M | 1 |
| Uemura, S | 1 |
| Albrecht, C; Bea, F; Blessing, E; Ieronimakis, N; Katus, HA; Konstandin, M; Kranzhöfer, A; Kranzhöfer, R; Morris-Rosenfeld, S; Preusch, MR; Shimizu, T; Vanakaris, A | 1 |
| Bessler, WK; Conway, SJ; DiStasi, MR; Downing, B; Ingram, DA; Kapur, R; Li, F; Mali, R; Mund, JA; Sarchet, KN; Stansfield, BK | 1 |
1 trial(s) available for fluorobenzenes and Neointima
| Article | Year |
|---|---|
Difference in statin effects on neointimal coverage after implantation of drug-eluting stents.
Topics: Aged; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Lipids; Male; Middle Aged; Neointima; Percutaneous Coronary Intervention; Pravastatin; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Tomography, Optical Coherence; Treatment Outcome | 2014 |
5 other study(ies) available for fluorobenzenes and Neointima
| Article | Year |
|---|---|
Rosuvastatin suppresses the oxidative response in the venous limb of an arteriovenous fistula and enhances the fistula blood flow in diabetic rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aorta, Abdominal; Arteriovenous Shunt, Surgical; Blood Flow Velocity; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Fluorobenzenes; Graft Occlusion, Vascular; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Neointima; Oxidative Stress; Pyrimidines; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Rosuvastatin Calcium; Sulfonamides; Superoxides; Time Factors; Vena Cava, Inferior | 2014 |
Acceleration of re-endothelialization and inhibition of neointimal formation using hybrid biodegradable nanofibrous rosuvastatin-loaded stents.
Topics: Animals; Arteries; Biocompatible Materials; Blood Platelets; Collagen Type I; Drug-Eluting Stents; Endothelium, Vascular; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nanofibers; Neointima; Propanols; Pyrimidines; Rabbits; Rosuvastatin Calcium; Sulfonamides | 2014 |
Statins and prevention of stent-related late adverse events.
Topics: Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neointima; Percutaneous Coronary Intervention; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2014 |
Rosuvastatin reduces neointima formation in a rat model of balloon injury.
Topics: Animals; Carotid Arteries; Catheterization; Disease Models, Animal; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinase 9; Neointima; Pyrimidines; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Sulfonamides | 2010 |
Heterozygous inactivation of the Nf1 gene in myeloid cells enhances neointima formation via a rosuvastatin-sensitive cellular pathway.
Topics: Animals; Anti-Inflammatory Agents; Arterial Occlusive Diseases; Bone Marrow Cells; Fluorobenzenes; Heterozygote; Humans; Macrophages; Metabolic Networks and Pathways; Mice; Myeloid Cells; Neointima; Neurofibromatosis 1; Neurofibromin 1; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2013 |